GP5 and cervical cancer: Considering that GP5+/6+ PCR EIA has long been the benchmark for evaluating new HPV DNA tests for cervical cancer screening purposes, and, in combination with prior AF, has been used for long-term vaccine monitoring studies, our comparisons suggest that Allplex HPV28 can become an alternative for HPV genotyping in FVU samples.